Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients

Journal of Rheumatology

Volumn 35, Issue 1, 2008, Pages 100-105

  Faurschou, Mikkel ^a   Sorensen, Inge Juul ^b   Mellemkjaer, Lene ^c   Loft, Anne Gitte Rasmussen ^d   Thomsen, Bjarne Svalgaard ^d   Tvede, Niels ^a   Baslund, Bo ^a  

^a Rigshospitalet   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute myeloid leukemia; Bladder cancer; Cyclophosphamide; Skin cancer; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; PREDNISOLONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN CANCER; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTAGENS; NEOPLASMS; WEGENER GRANULOMATOSIS;

EID: 38149112725     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
3. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 2006;18:25-32.
4. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
5. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737-47.
6. de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
7. Worth PH. Cyclophosphamide and the bladder. BMJ 1971;3:182.
8. Pedersen-Bjergaard J, Specht L, Larsen SO, et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2:83-8.
9. Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988;318:1028-32.
10. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-30.
11. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987;83:1-9.
12. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7.
13. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
14. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
15. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
16. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
17. Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004;63:1307-11.
18. Activity in the hospital care system 1979 [Danish]. Copenhagen: Danish National Board of Health; 1981.
19. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
20. Cancer incidence in Denmark 1996. Copenhagen: Danish National Board of Health; 1999.
21. International classification of diseases for oncology. 1st ed. Geneva: World Health Organization; 1976.
22. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154:498-504.
23. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996;61:715-21.
24. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513-9.
25. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006;54:1608-18.
26. Hellmich B, Kausch I, Doehn C, Jocham D, Holl-Ulrich K, Gross WL. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 2004;63:1183-5.
27. Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999;42:751-6.
28. Villa-Forte A, Hoffman GS. Wegener's granulomatosis presenting with a renal mass. J Rheumatol 1999;26:457-8.
29. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
30. Baecklund E, Backlin C, Iliadou A, et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006;54:3774-81.
31. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
32. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
33. Luqmani RA, Mukhtyar C, Guillevin L. EULAR recommendations for vasculitis [abstract]. Ann Rheum Dis 2007;66:44.
34. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.